Fundraising FoxNew Alliance Capital
Private equityShanghai · Seed–Late Stage · 25 people tracked
Find your way into New Alliance Capital
Sign up to see every warm intro you have to New Alliance Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the New Alliance Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
New Alliance Capital invests across information technology, healthcare, and future/frontier technology, backing companies at early, growth, and mature stages. Rooted in hard-tech industries, the firm emphasizes value-added services, drawing on its team's experience in state-enterprise restructuring, private venture investing, and multinational localization. It leverages industry and research resources to provide financial and strategic support to Chinese companies and entrepreneurs, aiming to nurture industry leaders with international competitiveness. The firm has completed over 150 investments, with more than 30 portfolio companies listed publicly, and manages multiple funds with cumulative assets exceeding RMB 17 billion.
Source: firm website, verified Aug 3, 2026.
Team · 25 people
from the firm's website & public directories
What they invest in
from 2 of 2 portfolio companiesBiotech ×2AI & Machine Learning ×1Deep Tech ×1Healthtech ×1
HQs:United States×1
Investments · 2 tracked
founders shown can be your intro path
Arnatar develops a next-generation RNA discovery platform called DARGER that combines gene silencing and gene upregulation technologies for oligonucleotide therapeutics.
AI & Machine LearningBiotechDeep Tech
Dr. Xuehai Liang(Founder)Dr. Yanfeng Wang(Founder & Chief Operating Officer)
Co-investors3E Bioventures CapitalF-Prime CapitalApricot CapitalEight Roads VenturesGaorong VenturesLegend Star
Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease.
BiotechHealthtechCambridge, US
Jingye Zhou(Founder)inJingye Zhou, Ph.D.(Co-founder & CEO)Jianfeng Xu, Ph.D.(Co-founder & CSO)
Co-investorsDelos Capital
Portfolio news
latest coverage across their companiesArnatar Therapeutics · biospace.com · Aug 25, 2025
Frequently asked questions
- What stage does New Alliance Capital invest at?
- New Alliance Capital invests at the Seed, Series A, Series B, Growth, Late Stage stages.
- What sectors does New Alliance Capital focus on?
- New Alliance Capital focuses on AI & Machine Learning, Biotech, Consumer, Data & Infrastructure, Deep Tech, Digital Health, Energy, Enterprise Software, Fintech, Healthtech, Media & Entertainment, Medical Devices, New Materials, Retail Tech, SaaS.
- Where is New Alliance Capital located?
- New Alliance Capital is headquartered in Shanghai, CN.
Similar investors
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Ameba Capital (阿米巴资本) is a China-focused venture capital firm founded in 2011 that invests in enterprise services and next-generation information technology companies from early to growth stage.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Industrial Technology Investment Corporation is the venture capital arm of Taiwan's Industrial Technology Research Institute (ITRI), backing startups across multiple stages and sectors while providing access to ITRI's R&D resources.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.